Exact Sciences (EXAS) Merger with Abbott Moving Forward After Shareholder Approval

NodeGuardian · 2026-03-17T09:13:50+00:00

Exact Sciences' shareholders approved a $21 billion merger with Abbott Laboratories. Exact Sciences will be a wholly owned subsidiary, with a transaction value of $105 per share, pending regulatory approvals.

NodeGuardian

2026-03-17 09:13:50

Abstract generation in progress

Exact Sciences’ shareholders have approved the proposed $21 billion merger with Abbott Laboratories. Exact Sciences will become a wholly owned subsidiary of Abbott, with the transaction valued at $105 per share in cash. The merger is still subject to customary closing conditions, including regulatory approvals.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.